HARRIGAN EDMUND — SEC insider filings

SEC reporting owner CIK 1177917. 43 insider filings on record with FilingPulse; latest filed 2026-10-02.

Transaction summary — filings shown

Covers all 43 filings on record, filed 2020-08-14 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Karuna Therapeutics, Inc. (KRTX)Director1—1 leg · 10,000 sh · $833,200—
PhaseBio Pharmaceuticals Inc (PHAS)Director41 leg · 6,000 sh · $24,720—5
INCYTE CORP (INCY)Director32——38
ACADIA PHARMACEUTICALS INC (ACAD)Director6——24

Insider filings — HARRIGAN EDMUND

FiledFormIssuerReported transactionsSource
2026-10-024INCYTE CORP (INCY)Grant/award (A): 206 @ $121.35EDGAR
2026-07-024INCYTE CORP (INCY)Grant/award (A): 255 @ $113.36EDGAR
2026-06-104INCYTE CORP (INCY)Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0EDGAR
2026-06-014ACADIA PHARMACEUTICALS INC (ACAD)Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0EDGAR
2026-04-024INCYTE CORP (INCY)Grant/award (A): 269 @ $94.12EDGAR
2026-01-054INCYTE CORP (INCY)Grant/award (A): 245 @ $98.77EDGAR
2025-10-024INCYTE CORP (INCY)Grant/award (A): 289 @ $84.81EDGAR
2025-07-024INCYTE CORP (INCY)Grant/award (A): 367 @ $68.10EDGAR
2025-06-124INCYTE CORP (INCY)Grant/award (A): 2,518 @ $0 · Grant/award (A): 9,216 (derivative) @ $0EDGAR
2025-06-024ACADIA PHARMACEUTICALS INC (ACAD)Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0EDGAR
2025-04-024INCYTE CORP (INCY)Grant/award (A): 363 @ $60.55EDGAR
2025-01-034INCYTE CORP (INCY)Grant/award (A): 339 @ $69.07EDGAR
2024-10-024INCYTE CORP (INCY)Grant/award (A): 378 @ $66.10EDGAR
2024-07-024INCYTE CORP (INCY)Grant/award (A): 409 @ $60.62EDGAR
2024-06-144INCYTE CORP (INCY)Grant/award (A): 2,830 @ $0 · Grant/award (A): 12,517 (derivative) @ $0EDGAR
2024-05-314ACADIA PHARMACEUTICALS INC (ACAD)Option exercise (M): 6,652 · Option exercise (M): 6,652 (derivative) @ $0 · Grant/award (A): 15,959 (derivative) @ $0 · Grant/award (A): 9,387 (derivative) @ $0EDGAR
2024-04-024INCYTE CORP (INCY)Grant/award (A): 413 @ $56.97EDGAR
2024-01-034INCYTE CORP (INCY)Grant/award (A): 423 @ $62.79EDGAR
2023-10-034INCYTE CORP (INCY)Grant/award (A): 389 @ $57.77EDGAR
2023-07-054INCYTE CORP (INCY)Grant/award (A): 390 @ $62.25EDGAR
2023-06-164INCYTE CORP (INCY)Grant/award (A): 2,505 @ $0 · Grant/award (A): 11,294 (derivative) @ $0EDGAR
2023-06-054ACADIA PHARMACEUTICALS INC (ACAD)Option exercise (M): 3,059 · Option exercise (M): 6,391 · Option exercise (M): 8,552 · Option exercise (M): 3,059 (derivative) @ $0 · Option exercise (M): 6,391 (derivative) @ $0 · Option exercise (M): 8,552 (derivative) @ $0 · +2 moreEDGAR
2023-05-194PhaseBio Pharmaceuticals Inc (PHAS)Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2023-04-044INCYTE CORP (INCY)Grant/award (A): 326 @ $72.27EDGAR
2023-01-044INCYTE CORP (INCY)Grant/award (A): 302 @ $80.32EDGAR
2022-10-204INCYTE CORP (INCY)Grant/award (A): 165 @ $69.59EDGAR
2022-10-044INCYTE CORP (INCY)Grant/award (A): 250 @ $66.64EDGAR
2022-07-014INCYTE CORP (INCY)Grant/award (A): 236 @ $75.97EDGAR
2022-06-174INCYTE CORP (INCY)Grant/award (A): 2,144 @ $0 · Grant/award (A): 9,124 (derivative) @ $0EDGAR
2022-06-094ACADIA PHARMACEUTICALS INC (ACAD)Grant/award (A): 14,368 (derivative) @ $0 · Grant/award (A): 8,552 (derivative) @ $0EDGAR
2022-05-204PhaseBio Pharmaceuticals Inc (PHAS)Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-04-044INCYTE CORP (INCY)Grant/award (A): 240 @ $79.42EDGAR
2022-01-044INCYTE CORP (INCY)Grant/award (A): 253 @ $73.40EDGAR
2021-10-044INCYTE CORP (INCY)Grant/award (A): 237 @ $68.78EDGAR
2021-07-024INCYTE CORP (INCY)Grant/award (A): 208 @ $84.13EDGAR
2021-06-244ACADIA PHARMACEUTICALS INC (ACAD)Grant/award (A): 11,637 (derivative) @ $0 · Grant/award (A): 6,391 (derivative) @ $0EDGAR
2021-06-044PhaseBio Pharmaceuticals Inc (PHAS)Grant/award (A): 14,000 (derivative) @ $0EDGAR
2021-05-284INCYTE CORP (INCY)Grant/award (A): 1,923 @ $0 · Grant/award (A): 8,010 (derivative) @ $0EDGAR
2021-04-014INCYTE CORP (INCY)Grant/award (A): 219 @ $81.27EDGAR
2021-01-054INCYTE CORP (INCY)Grant/award (A): 207 @ $86.98EDGAR
2020-12-044PhaseBio Pharmaceuticals Inc (PHAS)Purchase (P): 6,000 @ $4.12EDGAR
2020-10-014INCYTE CORP (INCY)Grant/award (A): 187 @ $89.74EDGAR
2020-08-144Karuna Therapeutics, Inc. (KRTX)Sale (S): 10,000 @ $83.32EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1177917 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs